Search Results - "Miller, David H"

Diagnosis of multiple sclerosis: progress and challenges by Brownlee, Wallace J, Dr, Hardy, Todd A, PhD, Fazekas, Franz, Prof, Miller, David H, Prof

“…Summary The diagnosis of multiple sclerosis is based on neurological symptoms and signs, alongside evidence of dissemination of CNS lesions in space and time…”
Get full text

Optic neuritis by Toosy, Ahmed T, Dr, Mason, Deborah F, FRACP, Miller, David H, Prof

“…Summary Acute optic neuritis is the most common optic neuropathy affecting young adults. Exciting developments have occurred over the past decade in…”
Get full text

Clinically isolated syndromes by Miller, David H, Prof, Chard, Declan T, PhD, Ciccarelli, Olga, PhD

“…Summary Clinically isolated syndrome (CIS) is a term that describes a first clinical episode with features suggestive of multiple sclerosis (MS). It usually…”
Get full text

Baló's concentric sclerosis by Hardy, Todd A, Dr, Miller, David H, Prof

“…Summary Baló's concentric sclerosis is often regarded as a rare variant of multiple sclerosis. Patients with this disorder present with acute or subacute…”
Get full text

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study by Connick, Peter, MRCP, Kolappan, Madhan, MRCP, Crawley, Charles, FRCP, Webber, Daniel J, PhD, Patani, Rickie, MRCP, Michell, Andrew W, PhD, Du, Ming-Qing, Prof, Luan, Shi-Lu, PhD, Altmann, Daniel R, PhD, Thompson, Alan J, Prof, Compston, Alastair, Prof, Scott, Michael A, PhD, Miller, David H, Prof, Chandran, Siddharthan, Prof

“…Summary Background More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of…”
Get full text

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis by Fox, Robert J, Miller, David H, Phillips, J. Theodore, Hutchinson, Michael, Havrdova, Eva, Kita, Mariko, Yang, Minhua, Raghupathi, Kartik, Novas, Mark, Sweetser, Marianne T, Viglietta, Vissia, Dawson, Katherine T

“…In this trial involving patients with relapsing–remitting multiple sclerosis, BG-12 (dimethyl fumarate) reduced the annualized relapse rate and number of MRI…”
Get full text

Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging by Ciccarelli, Olga, PhD, Barkhof, Frederik, Prof, Bodini, Benedetta, PhD, Stefano, Nicola De, Prof, Golay, Xavier, Prof, Nicolay, Klaas, Prof, Pelletier, Daniel, Prof, Pouwels, Petra J W, PhD, Smith, Seth A, Prof, Wheeler-Kingshott, Claudia A M, PhD, Stankoff, Bruno, MD, Yousry, Tarek, Prof, Miller, David H, Prof

“…Summary The mechanisms underlying the pathogenesis of multiple sclerosis induce the changes that underpin relapse-associated and progressive disability…”
Get full text

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial by Lublin, Fred, Prof, Miller, David H, Prof, Freedman, Mark S, Prof, Cree, Bruce A C, Prof, Wolinsky, Jerry S, Prof, Weiner, Howard, Prof, Lubetzki, Catherine, Prof, Hartung, Hans-Peter, Prof, Montalban, Xavier, Prof, Uitdehaag, Bernard M J, Prof, Merschhemke, Martin, MD, Li, Bingbing, PhD, Putzki, Norman, MD, Liu, Fonda C, PharmD, Häring, Dieter A, PhD, Kappos, Ludwig, Prof

“…Summary Background No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator,…”
Get full text

Primary-progressive multiple sclerosis by Miller, David H, MD, Leary, Siobhan M, MD

“…Summary About 10–15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as…”
Get full text

Imaging outcomes for trials of remyelination in multiple sclerosis by Mallik, Shahrukh, Samson, Rebecca S, Wheeler-Kingshott, Claudia A M, Miller, David H

“…Trials of potential neuroreparative agents are becoming more important in the spectrum of multiple sclerosis research. Appropriate imaging outcomes are…”
Get full text

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial by Raftopoulos, Rhian, MRCP, Hickman, Simon J, FRCP, Toosy, Ahmed, MRCP, Sharrack, Basil, FRCP, Mallik, Shahrukh, MRCP, Paling, David, MRCP, Altmann, Daniel R, PhD, Yiannakas, Marios C, PhD, Malladi, Prasad, MSc, Sheridan, Rose, PhD, Sarrigiannis, Ptolemaios G, FRCP, Hoggard, Nigel, FRCR, Koltzenburg, Martin, FRCP, Gandini Wheeler-Kingshott, Claudia A M, PhD, Schmierer, Klaus, FRCP, Giovannoni, Gavin, FRCP, Miller, David H, FMedSci, Kapoor, Raju, Dr

“…Summary Background Acute demyelinating optic neuritis, a common feature of multiple sclerosis, can damage vision through neurodegeneration in the optic nerve…”
Get full text

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials by Barkhof, Frederik, Calabresi, Peter A, Miller, David H, Reingold, Stephen C

“…Multiple sclerosis is traditionally considered to be an inflammatory disease, but it also has a neurodegenerative component, which can manifest early in the…”
Get full text

Shadows, wraiths, and amoebas:the distinctive flops of Anton Webern in the United States by Miller, David H

“…On January 13, 1924, the music of Anton Webern was performed for the first time in the United States. It did not go well. Over the course of the next five…”
Get full text

Association between pathological and MRI findings in multiple sclerosis by Filippi, Massimo, Prof, Rocca, Maria A, MD, Barkhof, Frederik, Prof, Brück, Wolfgang, Prof, Chen, Jacqueline T, PhD, Comi, Giancarlo, MD, DeLuca, Gabriele, MD, De Stefano, Nicola, MD, Erickson, Bradley J, PhD, Evangelou, Nikos, Prof, Fazekas, Franz, Prof, Geurts, Jeroen JG, Prof, Lucchinetti, Claudia, Prof, Miller, David H, Prof, Pelletier, Daniel, Prof, Popescu, Bogdan F Gh, PhD, Lassmann, Hans, Prof

“…Summary The identification of pathological processes that could be targeted by therapeutic interventions is a major goal of research into multiple sclerosis…”
Get full text

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study by Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Polman, Chris H, Prof, Edan, Gilles, Prof, Hartung, Hans-Peter, Prof, Miller, David H, Prof, Montalbán, Xavier, Prof, Barkhof, Frederik, Prof, Radü, Ernst-Wilhelm, Prof, Bauer, Lars, MD, Dahms, Susanne, PhD, Lanius, Vivian, PhD, Pohl, Christoph, MD, Sandbrink, Rupert, MD

“…Summary Background Several controlled studies provide evidence that treatment with interferon beta in patients with a first event suggestive of multiple…”
Get full text

Gray matter atrophy is related to long-term disability in multiple sclerosis by Fisniku, Leonora K., Chard, Declan T., Jackson, Jonathan S., Anderson, Valerie M., Altmann, Daniel R., Miszkiel, Katherine A., Thompson, Alan J., Miller, David H.

“…Objective To determine the relation of gray matter (GM) and white matter (WM) brain volumes, and WM lesion load, with clinical outcomes 20 years after first…”
Get full text

Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis by Liu, Zheng, Pardini, Matteo, Yaldizli, Özgür, Sethi, Varun, Muhlert, Nils, Wheeler-Kingshott, Claudia A M, Samson, Rebecca S, Miller, David H, Chard, Declan T

“…In multiple sclerosis, there is increasing evidence that demyelination, and neuronal damage occurs preferentially in cortical grey matter next to the outer…”
Get full text

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial by Kapoor, Raju, FRCP, Furby, Julian, MRCP, Hayton, Thomas, MRCP, Smith, Kenneth J, Prof, Altmann, Daniel R, PhD, Brenner, Robert, FRCP, Chataway, Jeremy, FRCP, Hughes, Richard AC, Prof, Miller, David H, Prof

“…Summary Background Partial blockade of voltage-gated sodium channels is neuroprotective in experimental models of inflammatory demyelinating disease. In this…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial by Kappos, Ludwig, MD, Freedman, Mark S, MD, Polman, Chris H, MD, Edan, Gilles, MD, Hartung, Hans-Peter, MD, Miller, David H, MD, Montalbán, Xavier, MD, Barkhof, Frederik, MD, Radü, Ernst-Wilhelm, MD, Metzig, Carola, MD, Bauer, Lars, MD, Lanius, Vivian, PhD, Sandbrink, Rupert, MD, Pohl, Christoph, MD

“…Summary Background The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with…”
Get full text